Twist Bioscience Corporation (TWST)

44.47 +2.82 (+6.77%) 收市：04:00PM EDT

Twist Bioscience Corporation

681 Gateway Boulevard
South San Francisco, CA 94080
United States
800 719 0671
https://www.twistbioscience.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 919

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Emily Marine Leproust Ph.D.	Co-Founder, Chairman & CEO	1.37M	153.71k	1973
Dr. Patrick John Finn Ph.D.	President & COO	943.94k	無	1972
Ms. Paula Green	Senior Vice President of Human Resources	618.48k	無	1968
Dr. William Charles Banyai Ph.D.	Senior VP of Advanced Development, GM of Data Storage & Director	711.34k	無	1955
Mr. Adam Laponis	Chief Financial Officer	無	無	1977
Mr. Robert F. Werner	VP & Chief Accounting Officer	無	無	1973
Mr. Siyuan Chen	Chief Technology Officer	無	無	無
Dr. Aaron K. Sato Ph.D.	Chief Scientific Officer	無	無	無
Mr. Chet Gandhi	Chief Information Officer	無	無	無
Mr. Dennis Cho	Senior VP, Chief Legal Officer & Corporate Secretary	537.93k	無	1971

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

公司管治

截至 2024年10月1日 止，Twist Bioscience Corporation 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：9；董事會：8；股東權利：7；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。